Shares of Syndax Pharmaceuticals Inc (NASDAQ:SNDX) have earned a consensus recommendation of “Buy” from the ten brokerages that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and nine have given a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $24.38.
Several brokerages have recently weighed in on SNDX. Zacks Investment Research raised shares of Syndax Pharmaceuticals from a “hold” rating to a “buy” rating and set a $10.00 price target on the stock in a research report on Wednesday, January 10th. B. Riley reissued a “buy” rating and set a $40.00 price target on shares of Syndax Pharmaceuticals in a research report on Thursday.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. California State Teachers Retirement System lifted its position in Syndax Pharmaceuticals by 60.9% in the second quarter. California State Teachers Retirement System now owns 15,587 shares of the company’s stock valued at $218,000 after buying an additional 5,900 shares during the last quarter. Alyeska Investment Group L.P. lifted its position in Syndax Pharmaceuticals by 1.8% in the third quarter. Alyeska Investment Group L.P. now owns 330,910 shares of the company’s stock valued at $3,872,000 after buying an additional 5,910 shares during the last quarter. New York State Common Retirement Fund lifted its position in Syndax Pharmaceuticals by 421.9% in the second quarter. New York State Common Retirement Fund now owns 9,400 shares of the company’s stock valued at $131,000 after buying an additional 7,599 shares during the last quarter. Teachers Advisors LLC lifted its position in Syndax Pharmaceuticals by 109.9% in the second quarter. Teachers Advisors LLC now owns 15,451 shares of the company’s stock valued at $216,000 after buying an additional 8,091 shares during the last quarter. Finally, Trexquant Investment LP acquired a new position in Syndax Pharmaceuticals in the third quarter valued at about $133,000. 61.65% of the stock is currently owned by institutional investors.
Syndax Pharmaceuticals (NASDAQ SNDX) opened at $9.58 on Friday. The firm has a market cap of $233.66 and a PE ratio of -3.39. Syndax Pharmaceuticals has a 1 year low of $6.31 and a 1 year high of $15.70.
Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings results on Tuesday, November 7th. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.80) by $0.12. The firm had revenue of $0.31 million for the quarter, compared to analysts’ expectations of $0.30 million. Syndax Pharmaceuticals had a negative net margin of 4,304.34% and a negative return on equity of 57.90%. The company’s revenue was up .0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.84) EPS. research analysts anticipate that Syndax Pharmaceuticals will post -2.92 earnings per share for the current year.
WARNING: This news story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another site, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/01/19/syndax-pharmaceuticals-inc-sndx-receives-consensus-recommendation-of-buy-from-analysts.html.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.